Nature Medicine
3, 151 - 152 (1997)
doi:10.1038/nm0297-151
Breast cancer and osteolytic metastases: Can bisphosphonates help?Ethel S. SirisDepartment of Medicine College of Physicians and Surgeons of Columbia University New York, New York 10032, USA Intravenous infusions of pamidronate ameliorate the skeletal complications of breast cancer metastases to bone.
REFERENCES
- Galasko, C.S.B. The anatomy and pathways of skeletal metastases. in Bone Metastasis, (eds. Weiss, L & Gilbert, A. H.) 49−63 (G. K. Hall, Boston, 1981).
- Hortobagyi, G.N. et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335, 1785−1791 (1996). | Article | PubMed | ISI | ChemPort |
- van Breukelen, F.J.M. et al. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1, 803−805 (1979). | Article | PubMed | ChemPort |
- Siris, E.S., Hyman, G.A. & Canfield, R.E. Effects of dichloromethylene bisphosphonate in women with breast cancer metastatic to the skeleton. Am. J. Med. 74, 401−406 (1983). | Article | PubMed | ISI | ChemPort |
- Elomaa, I. et al. Long-term controlled trial of bis-phosphonate in patients with osteolytic bone metastases. Lancet 1, 146−149 (1983). | Article | PubMed | ISI | ChemPort |
- Coleman, R.E. et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropyl-idene)-1, 1-bisphosphonate (APD) in patients with breast cancer. Br. J. Cancer 58, 621−625 (1988). | PubMed | ISI | ChemPort |
- Fleisch, H. & Russell, R.G.G. Pyrophosphate and polyphosphate. in Encyclopedia (Int.) of Pharma-cology and Therapeutics, Section 51. Pharmacology of the Endocrine System and Related Drugs. 61−100 (Pergamon, Oxford, New York, 1970).
- Watts, N.B. et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323, 73−79 (1990). | PubMed | ISI | ChemPort |
- Liberman, U. et al. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333, 1437−1443 (1995). | Article | PubMed | ISI | ChemPort |
- Kanis, J.A. Pathophysiology and Treatment of Paget's Disease of Bone. 159−216 (Dunitz, London, 1991).
- Jacobs, T.P. et al. Neoplastic hypercalcemia: Physio-logic response to intravenous etidronate disodium. Am. J. Med. 82 (Suppl. 2A), 42−50 (1987). | Article | PubMed | ISI | ChemPort |
- Nussbaum, S.R. et al. Single-dose intravenous ther-apy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30,60, and 90 mg dosages. Am. J. Med. 95, 297−304 (1993). | PubMed | ISI | ChemPort |
- Berenson, J.R. et al. Efficacy of pamidronate in re-ducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334, 488−493 (1996). | Article | PubMed | ISI | ChemPort |
- Morton, A.R. et al. Sclerosis of lytic bone metastases after disodium aminohydroxy-propylidene bisphos-phonate (APD) in patients with breast carcinoma. Br. Med. J. 297, 772−773 (1988). | ISI | ChemPort |
- Glover, D. et al. Intravenous pamidronate sodium treatment of bone metastases in patients with breast cancer: A dose seeking study. Cancer 74, 2949−2955 (1994). | PubMed | ISI | ChemPort |
- Rodan, G.A. & Rodan, S.B. Osteoporosis: Etiology, Diagnosis and Management, (eds. Riggs, B.L. & Melton, L.J.) 12 (Raven, New York, 1988).
|
